Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rhea N Coler

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
Clinical & Translational Immunology|December 20, 2016
A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.
Biorxiv : the Preprint Server for Biology|July 7, 2021
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samplesSasha E Larsen, Bryan J Berube, Tiffany Pecor, et al.
Journal of Immunological Methods|October 2, 2021
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samplesSasha E Larsen, Bryan J Berube, Tiffany Pecor, et al.
Tuberculosis (Edinburgh, Scotland)|December 31, 2022
Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimenMaham Rais, Hazem Abdelaal, Valerie A Reese, et al.
Vaccine|March 19, 2011
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasisJaya Chakravarty, Subodh Kumar, Sonali Trivedi, et al.
NPJ Vaccines|November 24, 2025
Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccineLisa A Jackson, Rhea N Coler, Gregory A Deye, et al.
Parasites & Vectors|July 6, 2016
Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasisPrakash Ghosh, Khondaker R H Bhaskar, Faria Hossain, et al.
NPJ Vaccines|September 14, 2018
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trialRhea N Coler, Tracey A Day, Ruth Ellis, et al.
Vaccine|November 3, 2009
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasisIván D Vélez, Katherine Gilchrist, Sofía Martínez, et al.
Frontiers in Immunology|November 12, 2024
The chosen few: <i>Mycobacterium tuberculosis</i> isolates for IMPAc-TBSasha E Larsen, Hazem F M Abdelaal, Courtney R Plumlee, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
Clinical & Translational Immunology|December 20, 2016
A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.
Biorxiv : the Preprint Server for Biology|July 7, 2021
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samplesSasha E Larsen, Bryan J Berube, Tiffany Pecor, et al.
Journal of Immunological Methods|October 2, 2021
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samplesSasha E Larsen, Bryan J Berube, Tiffany Pecor, et al.
Tuberculosis (Edinburgh, Scotland)|December 31, 2022
Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimenMaham Rais, Hazem Abdelaal, Valerie A Reese, et al.
Vaccine|March 19, 2011
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasisJaya Chakravarty, Subodh Kumar, Sonali Trivedi, et al.
NPJ Vaccines|November 24, 2025
Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccineLisa A Jackson, Rhea N Coler, Gregory A Deye, et al.
Parasites & Vectors|July 6, 2016
Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasisPrakash Ghosh, Khondaker R H Bhaskar, Faria Hossain, et al.
NPJ Vaccines|September 14, 2018
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trialRhea N Coler, Tracey A Day, Ruth Ellis, et al.
Vaccine|November 3, 2009
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasisIván D Vélez, Katherine Gilchrist, Sofía Martínez, et al.
Frontiers in Immunology|November 12, 2024
The chosen few: <i>Mycobacterium tuberculosis</i> isolates for IMPAc-TBSasha E Larsen, Hazem F M Abdelaal, Courtney R Plumlee, et al.
Pageof 14